Camlipixant
Phase 2Small molecule
GSKCamlipixant is one of 35 small molecule programs targeting Cough. It is currently in Phase 2.
2
Indications
5
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
185 competitors in Irritable Bowel Syndrome
#DrugCompanyPhaseTrials
1Lialda
TakedaPhase 3
Xifaxan
SSalix
Phase 3
Zofran
NovartisPhase 3
Amitiza
SSucampo Pharma Americas, LLC
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Zarontin
PParkedale
Phase 3
Mesalazine
FerringPhase 3
Saccharomyces Boulardii
BBiocodex
Phase 3
Trulance
SSalix
Phase 3
Lotronex
LLegacy Health System
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatic Impairment1 trial
A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
Completed·—·Phase 1·NCT06222892·32 enrolled
Tics1 trial
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
Completed·—·Phase 1·NCT05899829·42 enrolled
Drug Interactions1 trial
Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
Completed·—·Phase 1·NCT05959447·45 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Camlipixant. EMBL-EBI & Wellcome Sanger Institute.
- [4]